help Plz

**mattwho123** · 11-19-2008, 05:25 PM

i posted here yesterday about gyno

my buddy was taking 500 mgs test pw for 12wks and deca 300 pwfor 10wks
all he had was nolvadex for PCT bc he didnt think he was gyno prone
after a week and a half off the deca he stopped the cycle completely( was in to week 8) symptoms include a lump under his left nipple and there itchy.

I ordered him some arimidex that should be in about a week. He started the nolva yesterday at 40 mgs (first 2 weeks) the 20 mgs (second 2 weeks) i told him about nolva and 19 nors but its all he had .

the arimidex is 1mg/ml....when should he start talking the arimidex and for how long? ive only heard of running it .5mg eod or .25eod

**WARMachine** · 11-19-2008, 05:29 PM

Now that he has gyno, Adex and Nolva will do nothing for him...

**Ernst** · 11-19-2008, 05:31 PM

I would go letro on it if he's already sporting lady lumps.

All you need to know about GYNO.

**WARMachine** · 11-19-2008, 05:34 PM

^^^ X's 2

**mattwho123** · 11-19-2008, 05:35 PM

where can i order him some letro ?

**clockwork_killer** · 11-19-2008, 05:37 PM

ar-r the top banner mate, or jus click on letro

**Mulciber** · 11-19-2008, 05:37 PM

well, he is certainly in a spot isnt he.. need to plan for the unexpected.. anyway..

There are many studies showing tamoxifen 's efficacy in reducing tissue size and eliminating all symptoms of gyno after a few months use. for example.

"Sixty-one Chinese men with idiopathic gynecomastia were treated with 40 mg of tamoxifen daily for one of four months (median, two months). Eighty percent had complete regression of their breast swelling. No long-term side effects of tamoxifen were observed over a median follow-up period of 36 months."(1)

"Complete resolution of the gynecomastia was recorded in 18 patients (78.2%) treated with tamoxifen, whereas only 8 patients (40%) in the danazol group had complete resolution."(3)

1. Alagaratnam TT: Idiopathic gynecomastia treated with tamoxifen; a preliminary report. Clin Ther 9:483-7, 1987

2.Mathur R, Braunstein: Gynecomastia: Pathomechanisms and Treatment Strategies. Hormone Research 48:95-102, 1997.

3.Ting AC, Chow LW, Leung YF: Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg 66(1):38-40, 2000

Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia.

Ting AC, Chow LW, Leung YF.

Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam.

Idiopathic gynecomastia, unilateral or bilateral, is a common physical finding in normal men. Successful treatment using tamoxifen (antiestrogen) and danazol (antiandrogen) has recently been reported. We compared the efficacy of tamoxifen and danazol in the treatment of idiopathic gynecomastia. We reviewed the clinical records of patients with idiopathic gynecomastia presenting to the Department of Surgery, University of Hong Kong, between August 1990 and September 1995. Medical treatment with either tamoxifen (20 mg/d) or danazol (400 mg/d) was offered and continued until a static response was achieved. The treatment response was compared. Sixty-eight patients with idiopathic gynecomastia were seen in the Breast Clinic. The median age was 39.5 years (range, 13-82), with a median duration of symptoms of 3 months (range, 1-90). The median size was 3 cm (range, 1-7). Twenty-three patients were treated with tamoxifen and 20 with danazol. Complete resolution of the gynecomastia was recorded in 18 patients (78.2%) treated with tamoxifen, whereas only 8 patients (40%) in the danazol group had complete resolution. Five patients, all from the tamoxifen group, developed recurrence of breast mass. In conclusion, hormonal manipulation is effective in the treatment of patients with idiopathic gynecomastia. Although the effect is more marked for tamoxifen compared with danazol, the relapse rate is higher for tamoxifen. Further prospective randomized studies would be useful in defining the role of these drugs in the management of patients with idiopathic gynecomastia.

**Ernst** · 11-19-2008, 05:37 PM

Click on letro it'll take you straight there.

**WARMachine** · 11-19-2008, 05:43 PM

Originally Posted by Mulciber

well, he is certainly in a spot isnt he.. need to plan for the unexpected.. anyway..

There are many studies showing tamoxifen 's efficacy in reducing tissue size and eliminating all symptoms of gyno after a few months use. for example.

"Sixty-one Chinese men with idiopathic gynecomastia were treated with 40 mg of tamoxifen daily for one of four months (median, two months). Eighty percent had complete regression of their breast swelling. No long-term side effects of tamoxifen were observed over a median follow-up period of 36 months."(1)

"Complete resolution of the gynecomastia was recorded in 18 patients (78.2%) treated with tamoxifen, whereas only 8 patients (40%) in the danazol group had complete resolution."(3)

1. Alagaratnam TT: Idiopathic gynecomastia treated with tamoxifen; a preliminary report. Clin Ther 9:483-7, 1987

2.Mathur R, Braunstein: Gynecomastia: Pathomechanisms and Treatment Strategies. Hormone Research 48:95-102, 1997.

3.Ting AC, Chow LW, Leung YF: Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg 66(1):38-40, 2000

Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia.

Ting AC, Chow LW, Leung YF.

Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam.

Idiopathic gynecomastia, unilateral or bilateral, is a common physical finding in normal men. Successful treatment using tamoxifen (antiestrogen) and danazol (antiandrogen) has recently been reported. We compared the efficacy of tamoxifen and danazol in the treatment of idiopathic gynecomastia. We reviewed the clinical records of patients with idiopathic gynecomastia presenting to the Department of Surgery, University of Hong Kong, between August 1990 and September 1995. Medical treatment with either tamoxifen (20 mg/d) or danazol (400 mg/d) was offered and continued until a static response was achieved. The treatment response was compared. Sixty-eight patients with idiopathic gynecomastia were seen in the Breast Clinic. The median age was 39.5 years (range, 13-82), with a median duration of symptoms of 3 months (range, 1-90). The median size was 3 cm (range, 1-7). Twenty-three patients were treated with tamoxifen and 20 with danazol. Complete resolution of the gynecomastia was recorded in 18 patients (78.2%) treated with tamoxifen, whereas only 8 patients (40%) in the danazol group had complete resolution. Five patients, all from the tamoxifen group, developed recurrence of breast mass. In conclusion, hormonal manipulation is effective in the treatment of patients with idiopathic gynecomastia. Although the effect is more marked for tamoxifen compared with danazol, the relapse rate is higher for tamoxifen. Further prospective randomized studies would be useful in defining the role of these drugs in the management of patients with idiopathic gynecomastia.